Epic Bloom Moment
  • Stock
  • Business
  • Investing
  • Politics
Investing

Accent Trial Data Demonstrates that Narmafotinib + Chemotherapy Combination Superior to Chemotherapy Alone

by admin May 15, 2025
written by admin May 15, 2025

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce important new data from our ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Fifteen (15) confirmed partial responses (PRs) have now been recorded in the trial, a level of response sufficient to demonstrate that the combination of narmafotinib and chemotherapy is superior to chemotherapy alone.

HIGHLIGHTS

  • Key milestone achieved, with 15 confirmed responses recorded in the ongoing Phase 1b/2a ACCENT trial
  • Sufficient confirmed responses have now been recorded to demonstrate that narmafotinib combined with chemotherapy is superior to chemotherapy alone.
  • The ACCENT trial is evaluating narmafotinib in combination with the chemotherapies gemcitabine and Abraxane® in patients with advanced pancreatic cancer
  • Narmafotinib is a highly potent and selective FAK inhibitor discovered at the Melbourne-based Cooperative Research Centre for Cancer Therapeutics.
  • Phase 2a ACCENT trial is fully recruited with top-line data expected in mid Q3 2025

A confirmed partial response is a formal designation of response where tumour shrinkage >30% is recorded and sustained for two (2) or more months and where no new cancerous lesions have been detected. As pancreatic cancer is highly aggressive it is extremely rare for patients to achieve a complete response (CR).

The ACCENT trial is an open-label study meaning that all patients on the study receive narmafotinib in combination with the standard-of-care therapy. The data obtained in this trial is compared to historical data for the combination of gemcitabine and Abraxane in pancreatic cancer, and specifically data from the MPACT study, upon which we have closely modelled our trial1.

At the outset of the study a statistical analysis was performed which identified that a patient cohort of 50 patients would be sufficient to allow the efficacy of our combination to be ascertained with reasonable confidence if 15 or more responders (confirmed PR or CR) were recorded. A total of 55 advanced pancreatic patients have enrolled in the study since January 2024, with 21 patients still on study at this time.

As noted in our recent press release2, the drug continues to be well tolerated by patients with the rate and type of adverse events for the narmafotinib combination being similar to that reported for chemotherapy alone.

Amplia CEO and MD Dr Chris Burns commented: “We are extremely excited to have now recorded 15 confirmed partial responses in the ACCENT trial, demonstrating the benefit of adding narmafotinib to standard-of-care chemotherapy. With over 20 patients still on study we are hopeful that further PR’s will be observed”

Click here for the full ASX Release

This post appeared first on investingnews.com

0 comment
0
FacebookTwitterPinterestEmail
admin

previous post
Eric Nuttall: Oil vs. Natural Gas Stocks, Plus 2025 Prices, Supply and Demand
next post
Republicans struggle with Trump’s mixed signals on ‘big, beautiful bill’

Related Posts

Lithium Universe LtdSpodumene Offtake Update

June 2, 2025

Cardiex Receives TGA Approval for CONNEQT Pulse Device

June 2, 2025

Blue Lagoon’s Dome Mountain Joins BC’s Select List...

June 2, 2025

Ore Reserve Quadruples for Rhyolite Ridge Project; Reaffirms...

June 2, 2025

Harmony Gold to Acquire MAC Copper in US$1.03...

June 2, 2025

Canadian Wildfires Force Mining Sector to Retreat as...

June 3, 2025

Crypto Market Recap: Circle Targets US$7.2 Billion IPO,...

June 3, 2025

West High YieldResources Ltd. Announces Proceeds from Exercise...

June 3, 2025

Top 10 Uranium-producing Countries

June 3, 2025

Development update – Collie graphite micronising facility

June 3, 2025

Lithium Universe LtdSpodumene Offtake Update

June 2, 2025

Cardiex Receives TGA Approval for CONNEQT Pulse Device

June 2, 2025

Blue Lagoon’s Dome Mountain Joins BC’s Select List...

June 2, 2025

Ore Reserve Quadruples for Rhyolite Ridge Project; Reaffirms...

June 2, 2025

Harmony Gold to Acquire MAC Copper in US$1.03...

June 2, 2025

Canadian Wildfires Force Mining Sector to Retreat as...

June 3, 2025

Crypto Market Recap: Circle Targets US$7.2 Billion IPO,...

June 3, 2025

West High YieldResources Ltd. Announces Proceeds from Exercise...

June 3, 2025

Top 10 Uranium-producing Countries

June 3, 2025

Development update – Collie graphite micronising facility

June 3, 2025

Leave a Comment Cancel Reply

Save my name, email, and website in this browser for the next time I comment.

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Stock News

    • The Best Five Sectors, #21

      June 3, 2025
    • Hedge Market Volatility with These Dividend Aristocrats & Sector Leaders

      June 3, 2025
    • What’s Next for Dollar Tree, CrowdStrike, and Broadcom? Watch These Setups

      June 3, 2025
    • Breakouts, Momentum & Moving Averages: 10 Must-See Stock Charts Right Now

      June 1, 2025
    • Week Ahead: NIFTY Stays In A Defined Range; Moving Past This Level Crucial For Resumption Of Upmove

      June 1, 2025
    • About us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 epicbloommoment.com | All Rights Reserved

    Epic Bloom Moment
    • Stock
    • Business
    • Investing
    • Politics